ABSTRACT
Regulatory T cells (Tregs) are key mediators of immunosuppression in ovarian cancer, yet strategies for selectively targeting tumor‐infiltrating Tregs remain limited. CD4+CCR8+ Tregs have been proposed as a highly suppressive subset, but their functional relevance and therapeutic potential require further investigation. Here, we demonstrate that CCR8 is preferentially expressed on tumor‐infiltrating CD4+ Tregs in syngeneic ID8 and B16 tumor models, accounting for a significantly higher proportion compared with CD4+ conventional T cells and CD8+ T cells (p < 0.001). Functionally, CD4+CCR8+ Tregs exhibited enhanced suppressive activity, markedly inhibiting IFN‐γ production by CD8+ T cells (p < 0.01). The antagonist AZ084 significantly impaired Treg differentiation and alleviated Treg‐mediated suppression in vitro (p < 0.01). In vivo, AZ084 treatment effectively suppressed tumor growth in both ovarian cancer and melanoma models (p < 0.01), accompanied by a reduction in tumor‐infiltrating CD4+CCR8+ Tregs and an increase in CD8+ T cell infiltration and effector function (p < 0.05). Importantly, AZ084 had minimal impact on splenic immune cell composition (p > 0.05), suggesting limited systemic immunotoxicity. Collectively, our findings identify CCR8 as a selective marker and functional regulator of tumor‐infiltrating Tregs. Targeting CCR8 with AZ084 represents a promising strategy to enhance antitumor immunity while preserving peripheral immune homeostasis, providing a potential therapeutic approach for ovarian cancer.
Keywords: AZ084, CCR8, chemokine, ovarian cancer, regulatory T cells
AZ084, a novel CCR8 antagonist, selectively targets tumor‐infiltrating CD4+CCR8+ Tregs, reduces their immunosuppressive function, and decreases IL‐10/TGF‐β production.

Abbreviations
- AZ084
CCR8 allosteric antagonist AZ084
- CCL1
C‐C motif chemokine ligand 1
- CCR8
C‐C chemokine receptor 8
- COI
conflicts of interest
- CTLA‐4
cytotoxic T‐lymphocyte‐associated protein 4
- DMSO
dimethyl sulfoxide
- ELISA
enzyme‐linked immunosorbent assay
- FACS
fluorescence‐activated cell sorting
- FBS
fetal bovine serum
- Foxp3
forkhead box P3
- H&E
hematoxylin and eosin
- ICB
immune checkpoint blockade
- IFN‐γ
interferon‐γ
- IL‐2
interleukin‐2
- IL‐10
interleukin‐10
- LAG‐3
lymphocyte activation gene‐3
- MACS
magnetic‐activated cell sorting
- MDSCs
myeloid‐derived suppressor cells
- MFI
mean fluorescence intensity
- OC
ovarian cancer
- PBMCs
peripheral blood mononuclear cells
- PBS
phosphate‐buffered saline
- PD‐1
programmed cell death protein 1
- PMN‐MDSCs
polymorphonuclear myeloid‐derived suppressor cells
- RPMI
Roswell Park Memorial Institute medium
- TAMs
tumor‐associated macrophages
- Tconv
conventional CD4+ T cells
- TGF‐β
transforming growth factor‐β
- TME
tumor microenvironment
- Tregs
regulatory T cells
1. Introduction
Ovarian cancer (OC) is a gynecological malignancy with high mortality, ranking as the fifth leading cause of cancer‐related deaths among women worldwide [1]. OC typically has vague symptoms and lacks early detection markers, resulting in most cases being diagnosed at an advanced stage [2]. Despite advancements in standard treatment strategies—including cytoreductive surgery, platinum‐based chemotherapy, and targeted maintenance therapies such as PARP inhibitors—the 5‐year survival rate for advanced‐stage patients remains below 30%. Notably, while targeted therapies have improved progression‐free survival in subsets of patients with homologous recombination deficiency, their efficacy is limited by acquired resistance and tumor heterogeneity. Therefore, novel and effective strategies to significantly improve clinical outcomes in OC patients are urgently needed.
The limited efficacy of immunotherapy is closely associated with the immunosuppressive tumor microenvironment (TME) in tumor tissues. This complex environment often contributes to the resistance of tumors to immunotherapy. Regulatory T cells (Tregs) are critical factors in the formation of an immunosuppressive microenvironment in OC tissues. Effector Tregs (eTregs) are the predominant type of Tregs in tumor tissues, with high activation, proliferation, and heterogeneity. Therefore, targeting eTregs to improve TME is considered a promising immunotherapeutic strategy. However, systemic depletion of Tregs based on surface molecules, such as CTLA‐4, CD25, and GITR, can lead to severe autoimmune diseases. Thus, finding effective targeting methods to specifically eliminate tumor‐infiltrating eTregs while preserving Tregs crucial for suppressing autoimmunity is a key challenge. Successful achievement of this would transform the TME from immunosuppression to immune activation, which is a critical goal in cancer immunotherapy.
Previous studies by our group showed that CCR8 was highly expressed on CD4+ Tregs in OC tissues, and that CD4+CCR8+ Tregs had a stronger suppressive function and proliferative ability. CD4+CCR8+ Tregs may be the main OC tumor eTregs that play a dominant role in OC immune escape [3].
The ID8 ovarian cancer model has become an important tool for dissecting immune interactions within the ovarian TME. Studies using this model include: induction of tumor‐associated macrophages into M1‐type macrophages [4], inhibition of tumor growth by immune checkpoint therapy (ICB) targeting Tregs [5], Each of these studies demonstrated the translational relevance of the ID8 model for evaluating immunotherapeutic therapies.
In this study, we constructed a mouse tumor model and demonstrated that CD4+ CCR8+ Tregs are the primary subset of tumor‐infiltrating CD4+ Tregs that exhibit a strong suppressive function. We further demonstrated that AZ084, a variant inhibitor of CCR8, inhibited the differentiation and development of Tregs, as well as the suppressive function of CD4+CCR8+ Tregs. Finally, we showed that AZ084 effectively inhibited tumor development in vivo.
2. Materials and Methods
2.1. CD4 + Tregs Cultured In Vitro
Sorted CD4+CCR8+ Tregs and CD4+CCR8− Tregs were washed and resuspended in X‐Vivo15 medium (Lonza) containing 5% human AB serum (Gemini) and 500 U/mL IL‐2 (Peprotech). Cells (1 × 105 cells/well) were plated in a 96‐well round‐bottomed plate and 20 μL/well anti‐CD3/CD28‐coated microbeads (Invitrogen) were added. When the cells were expanded two‐fold, the cell suspension was equally divided into two wells. The cells were then cultured for 14 days.
2.2. Co‐Culture Experiments and Suppression Assay
CD8+ T cells were isolated from PBMCs using human CD8 MicroBeads (Miltenyi Biotec) through magnetic‐activated cell sorting (MACS) with LS columns, achieving > 95% purity as verified by flow cytometry (FACS Canto II, BD Biosciences). Purified cells were activated for 48 h with plate‐bound anti‐CD3 (5 μg/mL) and soluble anti‐CD28 (2 μg/mL) in RPMI‐1640/10% FBS medium containing 100 IU/mL IL‐2.
For the co‐culture, activated CD8+ T cells (5 × 104 cells/well) were seeded with CD4+CCR8+ or CD4+CCR8− Tregs (1 × 104 cells/well) in 96‐well plates. The culture was maintained for 72 h with daily supplementation of IL‐2 (50 IU/mL). Subsequently, cells were harvested and analyzed by flow cytometry using anti‐CD8‐APC (BioLegend) and anti‐CD4‐PE‐Cy7 antibodies (BioLegend).
CD4+ T cells were isolated from human PBMCs using human CD4 MicroBeads (Miltenyi Biotec) according to the manufacturer's instructions. CD4+ responder T cells were labeled with 10 μM CFSE (Thermo Fisher Scientific). CFSE‐labeled CD4+ responder T cells (1 × 105) were then cocultured with sorted CD4+CCR8+ Tregs (1 × 105) or CD4+CCR8− Tregs (1 × 105) at a 1:1 ratio in 96‐well plates pre‐coated with anti‐CD3 and anti‐CD28 antibodies. After 96 h of coculture, cells were harvested and analyzed by flow cytometry.
2.3. Mouse Tumor Models
Ovarian cancer model: 3 × 106 ID8 cells in 100 μL PBS injected s.c. into the right flank. Melanoma model: 1 × 105 B16‐F10 cells (ATCC CRL‐6475) in 100 μL sterile PBS (Corning, 21–040‐CV) injected s.c. into the right flank.
AZ084 (MedChemExpress, HY‐132598), a potent CCR8 antagonist (Ki = 0.9 nmol/L) [6], was administered at 5 mg/kg i.p. injected. The dosing solution was prepared by first dissolving AZ084 in DMSO to generate a 10 mg/mL stock, which was then diluted 10‐fold in corn oil (final concentration: 1 mg/mL; 10% DMSO). Vehicle controls were 10% DMSO in corn oil. Mice received a 100 μL injection (equivalent to 0.1 mg of AZ084 for the treatment group) 5 days post tumor implantation.
Tumor size was monitored by caliper measurements and calculated using the formula (length × width2)/2. For the ovarian cancer model, measurements were recorded every 5 days from day 5, and tissues were harvested on day 70. For the melanoma model, measurements were recorded every 3 days from day 3, with harvest on day 20.
Blood samples were centrifuged at 3500 rpm for 10–15 min at 4°C to obtain serum. Serum biochemical analysis was conducted to assess liver and kidney functions using an automatic biochemical analyzer (Hitachi 3500). In addition, serum levels of anti‐dsDNA antibodies (Cusabio) and anti‐parietal cell antibodies (SAIPEISEN BIOLOGY) were measured by ELISA to evaluate potential autoimmune responses. Essential organs, including the heart, liver, spleen, lung, and kidneys, were fixed in 4% paraformaldehyde to prepare paraffin sections (4 μm). H&E staining was performed to visualize tissue structure, and the H&E images were observed and scanned using a microscope (Olympus VS120).
2.4. Proliferation Assay of Naive CD4 + T Cells
Obtain mouse spleens and generate a single‐cell suspension. Naive CD4+ T cells were negatively selected using the naive CD4+ T Cell Isolation Kit II (Miltenyi Biotec 130–104‐453) according to the manufacturer's protocol. The round bottom 96‐well plate was coated with 4 μg/mL CD3 monoclonal antibody (Invitrogen) at 4°C overnight, then 3 ng/mL TGF‐β, 5 ng/mL murine IL‐2 (Peprotech), 2 μg/mL CD28 monoclonal antibody (Invitrogen) were added, and the initial CD4+ T cells were adjusted to 1 × 105 cells/mL with X⁃Vivo 15 medium in the round bottom 96‐well plate, and then the liquid was changed semi‐quantitatively and passaged on every other day.
2.5. Flow Cytometry
Cells were stained with a fixable viability dye (eFluor 780) and surface antibodies against Anti‐CD4‐FITC, Anti‐CD8‐APC, Anti‐CD45‐PE/Cyanine7, Anti‐CD3‐Alexa Fluor 700, Anti‐CCR8‐BV421, Anti‐CD279‐Brilliant Violet 510, Anti‐CD152‐Brilliant Violet 605, Anti‐IL‐10‐PE/Cyanine7, Anti‐IL‐10‐APC, Anti‐TGF‐β‐APC and Anti‐CD223‐APC (BioLegend) for 30 min on ice. For intracellular cytokine detection, cells were stimulated with PMA (100 ng/mL) and ionomycin (1 μg/mL) in the presence of brefeldin A (10 μg/mL) for 3.5–4 h, followed by fixation, permeabilization, and staining for Foxp3 and IFN‐γ. A detailed gating strategy is shown in Figure S4.
2.6. Chemotactic Assay
The chemotactic response of CD4+CCR8+ and CD4+CCR8− Tregs to a CCL1 gradient (100 ng/mL) was assessed using a transwell system. Tregs were treated with AZ084 (0, 1, 5, 10 μg/mL) in the upper chamber. After 2.5 h of incubation, migrated cells were counted to calculate the chemotactic index.
2.7. Statistical Analysis
Data were analyzed using GraphPad prism 8.0 software (GraphPad Software Inc., San Diego, CA, USA). The data are expressed as mean ± standard deviation (SD), and p‐values < 0.05 were considered statistically significant. p‐values correlate with the following symbols: ns = not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
3. Results
3.1. CCR8 Is Selectively Highly Expressed on Tumor‐Infiltrating Tregs in the ID8 Tumor Model
To systematically investigate the impact of targeted intervention on CD4+CCR8+ Tregs in the tumor immune microenvironment and tumor progression, this study employed a syngeneic tumor transplantation murine model (Figure 1A). Flow cytometry was used to analyze CCR8 expression in CD4+ Tregs, conventional CD4+ T (CD4+ Tconv) cells, and CD8+ T cells from spleens, lymph nodes, peripheral blood, and tumor tissues (n = 4) (Figure 1B–E).
FIGURE 1.

The proportion of CD4+CCR8+ Tregs in tumors, lymph nodes, peripheral blood and spleens of the ID8 tumor model. (A) Flowchart of immune component detection in tumors, lymph nodes, peripheral blood, and spleens. (B) Representative plots of the proportion of CD4+CCR8+ Tregs in spleens. (C) Representative plots of the proportion of CD4+CCR8+ Tregs in lymph nodes. (D) Representative plots of the proportion of CD4+CCR8+ Tregs in peripheral blood of the ID8 tumor model. (E) Representative plots of the proportion of CD4+CCR8+ Tregs in tumors. (F) Statistical chart of the proportion of CD4+CCR8+ Tregs, CD4+CCR8+ Tconv cells and CD8+CCR8+ T cells in spleens, lymph nodes, peripheral blood and tumors (n = 4). (G) Statistical chart of the proportion of CD4+CCR8+ Tregs, CD4+CCR8+ Tconv cells and CD8+CCR8+ T cells in tumors (n = 4). Tregs, regulatory T cells; Tconv, conventional T cells. (*p < 0.05; **p < 0.01; ***p < 0.001).
In CD4+ Tregs, the proportion of CCR8+ cell subsets in tumor (79.53% ± 1.83%) was markedly higher than that in spleens (16.85% ± 3.1%), lymph nodes (20.90% ± 3.50%), and peripheral blood (26.38% ± 10.04%). Similarly, in CD4+ Tconv cells, the proportion of CCR8+ cell subsets in tumor (28.10% ± 3.15%) was significantly higher than that in spleens (9.50% ± 0.47%), lymph nodes (4.71% ± 2.85%), and peripheral blood (3.06% ± 0.77%). In CD8+ T cells, the proportion of CCR8+ cell subsets in tumors (23.08% ± 2.63%) was also higher than that in spleens (9.24% ± 0.47%), lymph nodes (7.71% ± 5.17%), and peripheral blood (7.54% ± 4.37%) (Figure 1F).
Additionally, we compared the proportion of CCR8+ cell subsets among CD4+ Tregs, CD4+ Tconv, and CD8+ T cells in the tumor. This comparison demonstrated that the proportion of CCR8+cell subsets was significantly higher in CD4+ Tregs (79.53% ± 1.83%) than that in CD8+ T (23.08% ± 2.63%) and CD4+ Tconv cells (28.10% ± 3.15%) (Figure 1G). Overall, these results showed that CCR8 was predominantly expressed in CD4+ Tregs and accounted for a major proportion of CD4+ Tregs in the ID8 tumor model, consistent with our results in human ovarian tumor.
3.2. Tumor‐Infiltrating CD4 + CCR8 + Tregs Exhibit Enhanced Suppressive Phenotypes and Inhibit CD8 + T Cells Function
We next investigated the inhibitory phenotype of CD4+CCR8+ Tregs in the ID8 tumor model. We analyzed the expression of inhibitory markers PD‐1, CTLA‐4, and LAG‐3 on CD4+CCR8+ Tregs isolated from spleens, tumors and peripheral blood (Figure 2A). The results showed that the proportion of PD‐1+CD4+CCR8+ Tregs (tumor: 78.89% ± 11.95 vs. spleen: 48.43% ± 11.44% vs. blood: 16.35% ± 7.02%), CTLA‐4+ CD4+CCR8+ Tregs (tumor: 48.75% ± 15.09% vs. spleen: 13.43% ± 5.23% vs. blood: 13.96% ± 6.36%) and LAG‐3+ CD4+CCR8+ Tregs (tumor: 73.88% ± 8.04% vs. spleen: 13.90% ± 6.63% vs. blood: 12.39% ± 5.86%) were markedly elevated in tumor (Figure 2B). These results suggest that CD4+CCR8+ Tregs in tumor exhibit stronger inhibitory phenotypes than those in spleens and peripheral blood. Moreover, the characteristics of CD4+CCR8+ Tregs in ID8 tumor model were consistent with those found in clinical patient samples, indicating that this mouse model can be used for subsequent experiments.
FIGURE 2.

Immunosuppressive phenotypic and function of CD4+CCR8+ Tregs. (A) Representative plots of inhibitory phenotype molecules of CD4+CCR8+ Tregs in spleens, peripheral blood, and tumor of tumor‐bearing mice. (B) Statistical chart of the proportion of inhibitory phenotypic molecules in CD4+CCR8+ Tregs in spleens, tumor, and peripheral blood (n = 9) groups. (C) Representative plots of IFN‐γ production of CD8+ T cells in three groups: Co‐cultured with CD4+CCR8+ Tregs or CD4+CCR8− Tregs or cultured alone. (D) Statistical chart of IFN‐γ production of CD8+ T cells in three groups: Co‐cultured with CD4+CCR8+ Tregs or CD4+CCR8− Tregs or cultured alone (n = 3). (E) Representative plots of proliferation levels of responder T cells co‐cultured with different groups of Treg cells. (F) Statistical chart of responder T‐cell proliferation among the indicated co‐culture groups. Tregs, regulatory T cells; NC, Negative Control. (*p < 0.05; **p < 0.01; ***p < 0.001).
Subsequently, we isolated CD8+ T cells, CD4+CCR8+ Tregs, and CD4+CCR8− Tregs from peripheral blood of the same healthy individuals (n = 3). CD8+ T cells were cultured alone or co‐cultured with CD4+CCR8+ Tregs or CD4+CCR8− Tregs. The results indicated that co‐culture with CD4+CCR8+ Tregs resulted in a significant decrease in IFN‐γ production in CD8+ T cells (11.27% ± 1.75%) compared with CD8+ T cells co‐cultured with CD4+CCR8− Tregs (18.17% ± 1.46%) or cultured alone (34.4% ± 4.50%). In addition, the MFI of IFN‐γ in CD8+ T cells was also markedly decreased in the CD4+CCR8+ Treg co‐culture group (Figure 2C,D).
To further compare the suppressive capacity of CD4+CCR8+ and CD4+CCR8− Tregs, CFSE‐labeled responder T cells were co‐cultured with sorted CD4+CCR8+ Tregs or CD4+CCR8− Tregs under identical stimulation conditions. The percentage of proliferating responder T cells was significantly lower in the CD4+CCR8+ Treg coculture group (0.89% ± 0.07%) than in the CD4+CCR8− Treg coculture group (61.57% ± 2.12%), suggesting that CD4+CCR8+ Tregs possess stronger suppressive activity than CD4+CCR8− Tregs under the present co‐culture conditions (Figure 2E,F). Collectively, these results suggest that CD4+CCR8+ Tregs display enhanced suppressive features compared with CD4+CCR8− Tregs and may contribute to impaired effector T‐cell responses by reducing CD8+ T‐cell IFN‐γ production and inhibiting responder T‐cell proliferation.
3.3. The CCR8 Antagonist AZ084 Inhibits Tregs Differentiation and Immunosuppressive Function
Although CCR8 can be targeted by both antibodies and antagonists, the latter remains comparatively understudied. To investigate the effect of CCR8 on CD4+ Tregs, we used the allosteric inhibitor AZ084 in vitro. To understand the role of CCR8 in the differentiation of naïve CD4+ T cells into CD4+ Tregs, naïve CD4+ T cells were isolated from the spleens of C57BL/6 mice and cultured in differentiation conditions with DMSO or AZ084 (n = 5). The results indicated that the proportion of induced CD4+ Tregs was significantly reduced in the AZ084‐treated group (56.00% ± 7.29%) compared to the PBS (83.24% ± 8.47%) and DMSO groups (68.64% ± 7.61%) (Figure 3A,B), which highlights the important role of CCR8 in this process.
FIGURE 3.

The CCR8 antagonist AZ084 inhibits Tregs differentiation and immunosuppressive function. (A) Representative plots of the proportion of naïve CD4+ T cells differentiating to CD4+ Tregs in PBS, DMSO, and AZ084 groups. (B) Statistical chart of naïve CD4+ T cells differentiating to CD4+ Tregs and MFI of Foxp3 in PBS, DMSO, and AZ084 groups (n = 5). (C) Representative plots of the expression of IFN‐γ in CD8+ T cells after co‐culture with CD4+CCR8+ Tregs and treatment in the PBS, DMSO, and AZ084 groups. (D) Statistical chart of the expression of IFN‐γ in CD8+ T cells after co‐culture with CD4+CCR8+ Tregs and treatment in the PBS, DMSO, and AZ084 groups (n = 3). (E) Representative flow cytometry analysis of inhibitory phenotype molecules and cytokines of CD4+CCR8+ Tregs in four AZ084 concentrations. (F) Statistical chart of the proportion and MFI of inhibitory phenotypic molecules and cytokines of CD4+CCR8+ Tregs in four AZ084 concentrations (n = 3). (G) Chemotactic assay of CD4+CCR8+ Tregs in four AZ084 concentrations. (H) Comparative analysis of chemotactic responses in CD4+CCR8+ Treg in four AZ084 concentrations (n = 3). Tregs, regulatory T cells; DMSO, dimethyl sulfoxide; IFN‐γ, interferon‐γ; MFI, mean fluorescence intensity. (*p < 0.05; **p < 0.01; ***p < 0.001; NS, not significant).
To further investigate whether blocking CCR8 decreased the inhibitory effect of CD4+CCR8+ Tregs on CD8+ T cells, CD8+ T cells were co‐cultured with CD4+CCR8+ Tregs in the presence of PBS, DMSO, or AZ084. The results showed that CD8+ T cell function was significantly restored in the AZ084 group (9.51% ± 0.36%) compared to that in the PBS (1.28% ± 0.66%) and DMSO groups (5.69% ± 0.82%) (Figure 3C,D), showing that blocking CCR8 with the antagonist AZ084 can effectively counteract the immunosuppressive functions of CD4+CCR8+ Tregs. These findings highlight that CCR8 plays an important role in the differentiation and immunosuppressive functions of Tregs.
To investigate the dose‐dependent effects of AZ084, we sorted CD4+CCR8+ and CD4+CCR8− Tregs from human peripheral blood and treated them with 0, 1, 5, or 10 μg/mL of AZ084, respectively. Flow cytometry analysis revealed that AZ084 treatment at all concentrations did not alter the expression of immune checkpoint molecules on either subset at any concentration (p > 0.05). However, at a concentration of 1 μg/mL, AZ084 significantly suppressed TGF‐β expression but showed a non‐significant downward trend of IL‐10; at 5 μg/mL, the expression levels of TGF‐β were partially restored; at 10 μg/mL, an increase in IL‐10 and TGF‐β expression was observed (Figure 3E,F), while CD4+CCR8− Tregs remained unaffected (Figure S1A,B). The underlying mechanism requires further investigation; we speculate that it may be related to non‐specific cellular stress responses or the induction of alternative regulatory pathways.
Finally, chemotaxis induction assays demonstrated that the chemotaxis index of CD4+CCR8+ Tregs decreased significantly in a dose‐dependent manner with increasing AZ084 concentrations (Figure 3G,H). In contrast, the chemoattraction index of CD4+CCR8− Tregs showed no significant change (Figure S1C,D). These results indicate that AZ084 treatment significantly suppresses immunosuppressive factor secretion by CD4+CCR8+ Tregs and blocks the interaction between CCL1 and CCR8, thus effectively inhibiting the migration of these cells toward tumor.
3.4. The CCR8 Antagonist AZ084 Suppresses Tumor Growth in the Mouse Tumor Model
To further explore the effects of CCR8 blockade on tumor growth in vivo, we administered intraperitoneal injections of AZ084 to ovarian cancer and melanoma tumor mouse models and monitored the size and weight of the tumors. We treated the mice with AZ084, DMSO, or PBS (n = 6) (Figure 4A). In the ID8 tumor model, AZ084 treatment significantly reduced tumor volume compared to the PBS and DMSO groups. Meanwhile, there were no significant differences in spleens and lymph node sizes (Figure 4B). Tumor volume in the AZ084 group (62.51 ± 15.78 mm3) was markedly lower than that in the PBS group (162.3 ± 30.78 mm3) and DMSO group (147.6 ± 55.6 mm3). Consistently, tumor weight was also significantly decreased following AZ084 treatment (AZ084: 0.13 ± 0.03 g vs. DMSO: 0.26 ± 0.07 g vs. PBS: 0.27 ± 0.04 g) (Figure 4C).
FIGURE 4.

The CCR8 antagonist AZ084 inhibits tumor growth in mouse tumor model. (A) Schematic overview of anti‐tumor therapy in the ID8 tumor model. (B) Representative images of tumor‐bearing mice, tumors, spleens, and lymph nodes collected on day 70 from the ID8 tumor model. (C) Tumor weight (n = 6) and mean growth curves (n = 6) of ID8 tumor in mice treated with PBS, DMSO, and AZ084. (D) Schematic overview of anti‐tumor therapy in the B16 tumor model. (E) Representative images of tumor‐bearing mice, tumors, spleens, and lymph nodes collected on day 20 from the B16 tumor model. (F) Tumor weight (n = 6) and mean growth curves (n = 6) of B16 tumor in mice treated with PBS, DMSO, and AZ084. PBS, Phosphate‐Buffered Saline; DMSO, dimethyl sulfoxide (*p < 0.05; **p < 0.01; ***p < 0.001; NS, not significant).
In addition to the ID8 ovarian cancer model, we employed the B16 tumor model because of its representative immunogenic microenvironment and high experimental reproducibility. In the B16 tumor model, we used the same experimental groups as those in the ID8 tumor model (Figure 4D). AZ084 treatment markedly reduced tumor volume and weight compared with the PBS and DMSO groups, while no changes were detected in spleens or lymph node size (Figure 4E). Tumor volume in the AZ084 group (515 ± 171.3 mm3) was significantly lower than that in PBS (1168 ± 332.8 mm3) and DMSO groups (1120 ± 266.4 mm3). Tumor weight was also significantly decreased following AZ084 treatment (AZ084: 0.65 ± 0.22 g vs. DMSO: 1.46 ± 0.36 g vs. PBS: 1.36 ± 0.36 g) (Figure 4F). These findings demonstrated that intraperitoneal injection of AZ084 could effectively suppress tumor growth in mice without causing abnormalities in the peripheral immune system.
AZ084 significantly inhibited tumor growth in both ovarian cancer and melanoma models, suggesting that CCR8‐targeted therapy may have broad applicability across multiple Treg‐dependent tumor types.
3.5. Effect of the CCR8 Antagonist AZ084 on CD4 + CCR8 + Tregs and CD8 + T Cells in the Mouse Tumor Model
We analyzed immune cells in tumor from the ID8 and B16 tumor models using flow cytometry (n = 6). In the ID8 tumor model, the proportion of Foxp3+ subsets in CD4+ T cells was reduced in the AZ084 group (8.98% ± 1.16%) compared to that in the DMSO (13.93% ± 1.79%) and PBS groups (16.9% ± 3.96%), and MFI of Foxp3 in CD4+ Tregs was decreased following AZ084 treatment (AZ084: 265 ± 36.87 vs. DMSO: 309.5 ± 30.31 vs. PBS: 331.5 ± 19.69). Similarly, the proportion of CCR8+ cells within CD4+ Tregs was significantly reduced in the AZ084 group (65.25% ± 5.33%) compared with PBS (79.57% ± 9.20%) and DMSO groups (75.23% ± 9.05%), accompanied by a reduction in CCR8 MFI (AZ084: 60668 ± 3515 vs. DMSO: 77768 ± 10,703 vs. PBS: 82396 ± 6427) (Figure 5A,B). We next assessed the inhibitory phenotype of CD4+CCR8+ Tregs. Flow cytometry analysis showed that AZ084 treatment did not significantly alter the proportions or MFI values of PD‐1+, CTLA‐4+, LAG‐3+ subsets within CD4+CCR8+ Tregs compared with the PBS and DMSO groups. In addition, intracellular IL‐10 and TGF‐β expression in CD4+CCR8+ Treg cells was analyzed by flow cytometry. The results showed that the proportions of IL‐10 (AZ084: 17.23% ± 7.68% vs. DMSO: 28.05% ± 8.69% vs. PBS: 57.27% ± 6.85%) and TGF‐β (AZ084: 13.14% ± 7.52% vs. DMSO: 47.88% ± 11.5% vs. PBS: 56.25% ± 4.68%) producing CD4+CCR8+ Tregs were significantly reduced following AZ084 treatment (Figure 5C,D). Consistent results were observed for CD4+CCR8− Tregs (Figure S2A,B), in which neither the proportion of CD4+CCR8− Tregs nor the MFI values of PD‐1+, LAG‐3+ and CTLA‐4+ subsets were affected (Figure S2C,D).
FIGURE 5.

Effect of AZ084 on CD4+CCR8+ Tregs and CD8+ T cells of the ID8 tumor model. (A) Representative plots of CD4+ Tregs and CD4+CCR8+ Tregs. (B) Statistical chart of the proportion of CD4+ Tregs, CD4+CCR8+ Tregs and MFI of Foxp3, CCR8 (n = 6). (C) Representative plots of inhibitory phenotype molecules and cytokines of CD4+CCR8+ Tregs. (D) Statistical chart of the proportion, MFI of inhibitory phenotypic molecules and cytokines in CD4+CCR8+ Tregs (n = 6). (E) Representative flow cytometry plots of the proportion of CD8+ T cells and the production of IFN‐γ in CD8+ T cells. (F) Statistical chart of the proportion of CD8+ T cells and the production of IFN‐γ in CD8+ T cells (n = 6). MFI, mean fluorescence intensity; IFN‐γ, interferon‐γ. (*p < 0.05; **p < 0.01; ***p < 0.001; NS, not significant).
We subsequently evaluated the proportion and function of CD8+ T cells in the tumor tissues. In the ID8 tumor model, the proportion of CD8+ T cells was significantly increased in the AZ084 group (46.78% ± 11.95%) compared with PBS (23.03% ± 6.3%) and DMSO groups (30.80% ± 8.09%). In addition, IFN‐γ production by CD8+ T cells was significantly elevated following AZ084 treatment (AZ084: 39.77% ± 4.09% vs. DMSO: 18.48% ± 8.65% vs. PBS: 26.78% ± 4.71%) (Figure 5E,F). These results show that AZ084 influenced the proportion of CD4+ Tregs, CD4+CCR8+ Tregs, CD8+ T cells, and the production of IFN‐γ in CD8+ T cells in the tumor of the ID8 and B16 tumor models, but did not influence the expression of PD‐1, LAG‐3, and CTLA‐4 on CD4+CCR8+ Tregs and CD4+CCR8−Tregs.
To determine whether these findings were consistent across tumor types, the same analyses were performed in the B16 melanoma model. Similar results were observed, with the AZ084‐treated group showing significantly reduced proportions of Foxp3+ cells within CD4+ T cells and CCR8+ cells within CD4+ Tregs compared with the PBS and DMSO groups. In addition, AZ084 treatment significantly decreased the MFI of Foxp3 in CD4+ Tregs, whereas no significant difference in the CCR8 MFI was observed among the three groups (Figure S3A,B). Furthermore, there were no significant differences in the proportions or MFI values of PD‐1+, LAG‐3+, and CTLA‐4+ subsets in CD4+CCR8+ Tregs among the PBS, DMSO and AZ084 groups (Figure S3C–D). Notably, AZ084 treatment significantly increased the proportion of CD8+ T cells and enhanced IFN‐γ production by CD8+ T cells, indicating that AZ084 may promote antitumor immune responses in the B16 tumor microenvironment (Figure S3E–F).
3.6. The CCR8 Antagonist AZ084 Did Not Affect Peripheral Immunity in Mouse Tumor Model
To examine the potential impact of the CCR8 antagonist AZ084 on the peripheral immune system, we analyzed splenic immune cells from ID8 and B16 tumor‐bearing mice treated with PBS, DMSO, or AZ084 by flow cytometry. In the ID8 tumor model, no significant differences were observed in the proportion of CD4+ Tregs among the PBS (11.43% ± 4.03%), DMSO groups (8.97% ± 2.09%), and AZ084 groups (9.55% ± 2.78%). Similarly, there were no significant differences in the proportion of CD4+CCR8+ Tregs among groups (AZ084: 38.5% ± 12.76 vs. PBS: 27.68% ± 3.35% vs. DMSO: 30.63% ± 7.34%), and no significant differences were observed in the proportion of CD8+ T cells (AZ084: 21.47% ± 5.84% vs. PBS: 23.37% ± 5.53% vs. DMSO: 25.20% ± 2.28%). Statistical analysis indicates that these differences were not statistically significant (Figure 6A,B; p > 0.05).
FIGURE 6.

CCR8 antagonist AZ084 does not affect peripheral immunity in mouse tumor model. (A) Representative plots of CD4+ Tregs, CD4+CCR8+ Tregs, CD8+ T cells expression in spleens of ID8 tumor model in PBS, DMSO and AZ084 groups. (B) Statistical chart of the proportion of CD4+ Tregs, CD4+CCR8+ Tregs, CD8+ T cells in spleens of ID8 tumor model in PBS, DMSO and AZ084 groups (n = 6). (C) Representative plots of CD4+ Tregs, CD4+CCR8+ Tregs, CD8+ T cells expression in spleens of B16 tumor model in PBS, DMSO and AZ084 groups. (D) Statistical chart of the proportion of CD4+ Tregs, CD4+CCR8+ Tregs, CD8+ T cells in spleens of B16 tumor model in PBS, DMSO and AZ084 groups (n = 6). (E) Representative H&E staining images of hearts, livers, spleens, lungs and kidneys after indicated treatment of ID8 tumor model. Scale bar: 200 μm for hearts, liver, spleen, lung, and kidney. (F) Serum levels of anti‐dsDNA antibodies, anti‐parietal cell antibodies and biochemical evaluation for liver and kidney function of ID8 tumor model. H &E, hematoxylin and eosin; anti‐dsDNA, anti‐double‐stranded; PBS, Phosphate‐Buffered Saline; DMSO, dimethyl sulfoxide. (*p < 0.05; **p < 0.01; ***p < 0.001).
Consistent results were obtained in the B16 melanoma model. No significant differences were observed in the proportions of CD4+ Tregs, CD4+CCR8+ Tregs, and CD8+ T cells (Figure 6C,D; p > 0.05). Serum levels of anti‐dsDNA antibodies, anti‐parietal cell antibodies, and biochemical evaluation for liver and kidney function.
Furthermore, we analyzed serum levels of anti‐ds‐DNA antibody, anti‐parietal cell antibody, and biochemical evaluation for liver and kidney function (ALT, AST, CREA, TBIL), and performed histopathological examination of mouse tissues using H&E staining. The results indicated that no obvious abnormalities were observed in any of these assessments (Figure 6E,F; p > 0.05). These results suggest that AZ084 exerts limited effects on systemic immune homeostasis and does not cause obvious immune‐related toxicity under the experimental conditions used in this study.
4. Discussion
Cells that contribute to immunosuppression within the tumor microenvironment (TME) include Tregs, tumor‐associated macrophages (TAMs), myeloid‐derived suppressor cells (MDSCs), and cancer‐associated fibroblasts (CAFs) [7]. Among these, Tregs play a central role in maintaining immune tolerance and promoting tumor immune evasion.
Various strategies have been developed to target Tregs, including depletion, inhibition of recruitment, modulation of immune checkpoint blockade (ICB) responsiveness, and interference with suppressive signaling pathways [8]. However, systemic Treg depletion is often associated with immune‐related adverse events (irAEs) despite its antitumor effects [9]. eTregs, characterized by high activation and suppressive capacity, represent the predominant Treg subset within tumors [10]. Therefore, selectively targeting eTregs has emerged as an important strategy in cancer immunotherapy.
Chemokines and their receptors play critical roles in immune cell migration and tumor microenvironment remodeling. Among them, CCR4 and CCR8 have emerged as important targets for Treg modulation. CCR4 blockade can reduce intratumoral Tregs and enhance responsiveness to ICB [11, 12, 13]. CCR8, a receptor for ligands including CCL1, CCL8, CCL16, and CCL18, is preferentially expressed on tumor‐infiltrating Tregs in multiple cancers, including colorectal, breast, and bladder cancers, suggesting its potential as a selective therapeutic target for tumor‐resident Tregs [14, 15].
Our previous work confirmed that CD4+CCR8+ Tregs represent a predominant eTreg subset in ovarian cancer [3]. Current CCR8‐targeted strategies have largely focused on monoclonal antibodies designed to deplete CCR8+ Tregs via antibody‐dependent cellular cytotoxicity (ADCC). However, because CCR8 is also expressed in other immune cell populations, concerns remain regarding potential off‐target effects and systemic toxicity. In addition, recent studies have shown that CCR8 knockout models or CCR8‐targeting antibodies lacking ADCC activity are insufficient to deplete tumor‐infiltrating Tregs or suppress tumor growth, suggesting that CCR8 may not be strictly required for Treg accumulation due to compensatory mechanisms such as the CCL22–CCR4 axis. These findings suggest that strategies solely based on receptor deletion or non‐depleting blockade may have limited efficacy. Compared with monoclonal antibodies, CCR8 antagonists remain less extensively studied. AZ084, a small‐molecule CCR8 antagonist, blocks the interaction between CCR8 and its ligand CCL1 without directly depleting CCR8‐expressing cells, thereby representing a potentially complementary therapeutic strategy.
Currently studied CCR8 allosteric antagonists include AZ084 and IPG7236. In a mouse breast cancer tumor model, IPG7236 significantly inhibited tumor growth [16], whereas AZ084 has yet to be validated in animal models for its tumor growth inhibition. Compared to the CCR8 monoclonal antibodies currently under development, the small‐molecule allosteric antagonist AZ084 offers unique advantages; firstly it precisely blocks the CCL1‐CCR8 interaction through allosteric inhibition, avoiding the specific damage to Th2 cells and endothelial cells caused by the ADCC effect of monoclonal antibodies [6]; secondly it suppresses the expression of transcription factors FOXO1 and c‐MAF in Tregs, which causes them to shift from a stable to fragile state, effectively reducing their number and suppressive function [17]; finally its oral administration improves treatment adherence in clinical patients, making it especially suitable for late‐stage cancer patients requiring long‐term maintenance therapy. Based on these research findings, CCR8 allosteric antagonists are expected to become effective tools for eliminating CD4+ Tregs within tumor and alleviating immunosuppression in the tumor microenvironment.
In the present study, we observed that CD4+CCR8+ Treg cells represented a major immunosuppressive Treg subset within ovarian tumors and exhibited elevated expression of suppressive molecules, supporting the notion that CCR8 preferentially marks highly activated intratumoral Tregs. Importantly, treatment with the CCR8 antagonist AZ084 significantly reduced the proportion of tumor‐infiltrating CD4+CCR8+ Treg cells and effectively suppressed tumor growth in both ID8 ovarian cancer and B16 melanoma models. In addition, AZ084 treatment significantly decreased IL‐10 and TGF‐β expression in tumor‐infiltrating CD4+CCR8+ Treg cells, suggesting impaired suppressive function of these cells following CCR8 blockade. Notably, AZ084 treatment did not result in obvious alterations in major splenic immune cell populations, serum biochemical indicators, or histopathological findings under the tested conditions, indicating relatively limited short‐term systemic toxicity (Figure 7).
FIGURE 7.

AZ084, a novel CCR8 antagonist, selectively targets tumor‐infiltrating CCR8+ Tregs, reduces their immunosuppressive function, and decreases IL‐10/TGF‐β production.
Treg‐mediated immunosuppression is a key mechanism contributing to resistance to immune checkpoint blockade (ICB), particularly anti–PD‐1/PD‐L1 therapies. Although the current study did not directly evaluate AZ084 in ICB‐resistant tumor models or CCR8‐deficient mice, the observed reduction of CCR8+ Tregs and enhancement of CD8+ T cell function suggest that AZ084 may have the potential to overcome or alleviate ICB resistance. Future studies are warranted to investigate the efficacy of AZ084 in combination with immune checkpoint inhibitors or in models with established resistance to immunotherapy, which will further define its clinical applicability. Currently, we have only investigated two tumor models, focusing on CD4+CCR8+ Tregs, and have not observed the effects of AZ084 on the proportion and function of other CD4+ T cell subsets. Furthermore, mechanistic studies using genetic models, such as CCR8‐deficient mice, were not performed and will be important for further validating the context‐dependent role of the CCL1–CCR8 axis.
In conclusion, the above studies further confirmed the importance and specificity of CCR8 as a targeting site for tumor‐infiltrating Tregs and evaluated the effectiveness of AZ084 as a CCR8‐specific antagonist for treating solid tumors. Our results demonstrated that AZ084 is a potential therapeutic agent for cancer treatment.
Author Contributions
Yepeng Mao: conceptualization, data curation, formal analysis, visualization, writing – original draft, writing – review and editing. Ziqi Tao: data curation, formal analysis, writing – original draft, writing – review and editing. Shuna Liu: conceptualization, data curation, resources, writing – original draft, writing – review and editing. Zhijie Liu: formal analysis, writing – original draft, writing – review and editing. Yuelu Zhang: formal analysis, writing – original draft. Lingfei Zhou: formal analysis, writing – original draft. Lina Yan: formal analysis, writing – original draft. Ting Wang: conceptualization, formal analysis, writing – original draft. Wenwen Shang: formal analysis, writing – original draft. Jianfang Lou: formal analysis, writing – original draft. Xi Huang: formal analysis, writing – original draft. Xin Fu: formal analysis, writing – original draft. Fang Wang: conceptualization, data curation, formal analysis, funding acquisition, resources, writing – original draft, writing – review and editing.
Funding
This study was supported by National Natural Science Foundation of China (grant no. 82273199), Natural Science Foundation of Jiangsu Province (grant no. BK20221417), and Natural Science Foundation of Jiangsu Province for Young Scholars (grant no. BK20241123).
Ethics Statement
Studies involving human participants were reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University (Approval No. 2023‐SR‐350). Written informed consent was obtained from all participants. All animal experiments were conducted in accordance with institutional guidelines and were approved by the Animal Welfare and Ethics Committee of Nanjing Medical University (Approval No. IACUC‐2407013).
Conflicts of Interest
The authors declare no conflicts of interest.
Supporting information
Figure S1: Effects of AZ084 on CD4+CCR8− Tregs.
Figure S2: Effects of AZ084 on CD4+CCR8− Tregs of the ID8 tumor model.
Figure S3: Effects of AZ084 on CD4+CCR8+ Tregs and CD8+ T cells of the B16 tumor model.
Figure S4: Flow cytometry gating diagram for CD45+CD3+CD4+Foxp3+CCR8+ Tregs and downstream functional marker analysis.
Acknowledgments
The authors would like to express their gratitude to all the participants.
Data Availability Statement
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
References
- 1. Bray F., Laversanne M., Sung H., et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229–263. [DOI] [PubMed] [Google Scholar]
- 2. Lampert E. J., Cimino‐Mathews A., Lee J. S., et al., “Clinical Outcomes of Prexasertib Monotherapy in Recurrent BRCA Wild‐Type High‐Grade Serous Ovarian Cancer Involve Innate and Adaptive Immune Responses,” Journal for Immunotherapy of Cancer 8, no. 2 (2020): e000516. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Liu S., Tao Z., Lou J., et al., “CD4+CCR8+ Tregs in Ovarian Cancer: A Potential Effector Tregs for Immune Regulation,” Journal of Translational Medicine 21, no. 1 (2023): 803. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Xiong J., Huang J., Xu H., et al., “CpG‐Based Nanovaccines Enhance Ovarian Cancer Immune Response by Gbp2‐Mediated Remodeling of Tumor‐Associated Macrophages,” Advanced Science 12, no. 15 (2025): e2412881. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Chen F., Xu Y., Liu X., Dong N., and Tian L., “TIGIT+ CD4+ Regulatory T Cells Enhance PD‐1 Expression on CD8+ T Cells and Promote Tumor Growth in a Murine Ovarian Cancer Model,” Journal of Ovarian Research 17, no. 1 (2024): 252. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Wang M., Qin Z., Wan J., et al., “Tumor‐Derived Exosomes Drive Pre‐Metastatic Niche Formation in Lung via Modulating CCL1+ Fibroblast and CCR8+ Treg Cell Interactions,” Cancer Immunology, Immunotherapy: CII 71, no. 11 (2022): 2717–2730. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. de Visser K. E. and Joyce J. A., “The Evolving Tumor Microenvironment: From Cancer Initiation to Metastatic Outgrowth,” Cancer Cell 41, no. 3 (2023): 374–403. [DOI] [PubMed] [Google Scholar]
- 8. Shan F., Somasundaram A., Bruno T. C., Workman C. J., and Vignali D. A. A., “Therapeutic Targeting of Regulatory T Cells in Cancer,” Trends Cancer 8, no. 11 (2022): 944–961. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Zhang A., Fan T., Liu Y., et al., “Regulatory T Cells in Immune Checkpoint Blockade Antitumor Therapy,” Molecular Cancer 23, no. 1 (2024): 251. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Tanaka A. and Sakaguchi S., “Regulatory T Cells in Cancer Immunotherapy,” Cell Research 27, no. 1 (2017): 109–118. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Luo X., Huang W., Li S., et al., “SOX12 Facilitates Hepatocellular Carcinoma Progression and Metastasis Through Promoting Regulatory T‐Cells Infiltration and Immunosuppression,” Advanced Science 11, no. 36 (2024): e2310304. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Watanabe K., Gomez A. M., Kuramitsu S., et al., “Identifying Highly Active Anti‐CCR4 CAR T Cells for the Treatment of T‐Cell Lymphoma,” Blood Advances 7, no. 14 (2023): 3416–3430. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Gao Y., You M., Fu J., et al., “Intratumoral Stem‐Like CCR4+ Regulatory T Cells Orchestrate the Immunosuppressive Microenvironment in HCC Associated With Hepatitis B,” Journal of Hepatology 76, no. 1 (2022): 148–159. [DOI] [PubMed] [Google Scholar]
- 14. Nagira Y., Nagira M., Nagai R., et al., “S‐531011, a Novel Anti‐Human CCR8 Antibody, Induces Potent Antitumor Responses Through Depletion of Tumor‐Infiltrating CCR8‐Expressing Regulatory T Cells,” Molecular Cancer Therapeutics 22, no. 9 (2023): 1063–1072. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Campbell J. R., McDonald B. R., Mesko P. B., et al., “Fc‐Optimized Anti‐CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models,” Cancer Research 81, no. 11 (2021): 2983–2994. [DOI] [PubMed] [Google Scholar]
- 16. Wu Y., Xi J., Li Y., et al., “Discovery of a Potent and Selective CCR8 Small Molecular Antagonist IPG7236 for the Treatment of Cancer,” Journal of Medicinal Chemistry 66, no. 7 (2023): 4548–4564. [DOI] [PubMed] [Google Scholar]
- 17. Wang T., Zhou Q., Zeng H., et al., “CCR8 Blockade Primes Anti‐Tumor Immunity Through Intratumoral Regulatory T Cells Destabilization in Muscle‐Invasive Bladder Cancer,” Cancer Immunology, Immunotherapy: CII 69, no. 9 (2020): 1855–1867. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Figure S1: Effects of AZ084 on CD4+CCR8− Tregs.
Figure S2: Effects of AZ084 on CD4+CCR8− Tregs of the ID8 tumor model.
Figure S3: Effects of AZ084 on CD4+CCR8+ Tregs and CD8+ T cells of the B16 tumor model.
Figure S4: Flow cytometry gating diagram for CD45+CD3+CD4+Foxp3+CCR8+ Tregs and downstream functional marker analysis.
Data Availability Statement
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
